What's happening?

The analytical market has changed considerably over the years, and this has impacted the way that drug development teams approach analytical testing. As a result, the speed at which a product then reaches market has also been improved. 

By delivering therapeutic concentrations directly to the site of treatment, inhaled medicines can provide a fast onset of action while limiting systemic exposure.

The pharmaceutical industry is under immense pressure to reduce timelines and any associated costs when it comes to oral solid dosage (OSD) drug development and manufacturing. Many drug developers are choosing to unload some of this responsibility by outsourcing to contract development and manufacturing organisations (CDMOs).

There is an ever-growing market for oral solid dose development and the complex nature of new molecules has impacted outsourcing solid dose manufacturing in a number of ways. 

There is an ongoing risk of counterfeit medicines entering the legal supply chain and the pharmaceutical industry continues to take the necessary steps to tackle this problem. Various serialisation legislation has been introduced in key markets to improve the traceability of all medicines. 

The pharmaceutical supply chain has of course been impacted by COVID-19, with common issues including raw material delays and challenges with the shipment of goods. Increased border controls have further exacerbated this issue.

Andressa Barban do Patrocinio, Fernanda Janku Cabral, André Luiz Brandão Bitencourt, Olinda Mara Brigato, Lizandra Guidi Magalhães, Lucas Antônio de Lima Paula, Larissa Franco, Renata Guerra-Sá and Vanderlei Rodrigues
  Published online April 7, 2020  

Triggered by concerns surrounding global warming due to the consumption of greenhouse gases, the United Nations (UN) countries have committed to phase down global hydrofluoroalkane (HFA) consumption by 80-85% by 2047.

Over the years, there has been a shift in focus for drug formulators. The FDA expects the needs of the patient to be considered when developing new drug products, meaning today, the focus on the overall patient experience is a priortity.